PRMT3 and fatty liver disease: As such, pharmacological blockade of the PRMT3 function through treatment with the selective PRMT3 inhibitor SGC707 is able to overcome the LXR agonist-induced development of hepatic steatosis in C57BL/6 wild-type mice5.